{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:15:32Z","timestamp":1783116932647,"version":"3.54.6"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L242050"],"award-info":[{"award-number":["L242050"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128642","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:46:39Z","timestamp":1777383999000},"page":"128642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Vaccination strategies for responding to public health emergencies of infectious diseases"],"prefix":"10.1016","volume":"83","author":[{"given":"Yingtong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128642_bb0005","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2023.74","article-title":"Effects of public health emergencies of international concern on disease control: a systematic review","volume":"47","author":"de Araujo","year":"2023","journal-title":"Rev Panam Salud Publica"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002731","article-title":"Infection prevention and control measures to reduce the transmission of mpox a systematic review","volume":"4","author":"Kuehn","year":"2024","journal-title":"PLOS Glob Public Health"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128642_bb0015","first-page":"S210","article-title":"Lessons learned from emergency response vaccination efforts for cholera typhoid yellow fever and ebola","volume":"23","author":"Jenny","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128642_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.25259\/IJMR_750_2024","article-title":"Comparative efficacy of leading COVID-19 vaccines: a network meta-analysis","volume":"161","author":"Rai","year":"2025","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0025","article-title":"Vaccine licensure in the absence of human efficacy data","volume":"10","author":"Finch","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128642_bb0030","article-title":"Vaccine development throughout history","volume":"13","author":"Saleh","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.vaccine.2026.128642_bb0035","series-title":"WX. A brief history of vaccines. Shanghai: China: Shanghai Educational Publishing House","author":"Zhang","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128642_bb0040","series-title":"Vaccine--The Controversial Story of Medicine\u2019s Greatest Lifesaver","author":"Arthur","year":"2007"},{"key":"10.1016\/j.vaccine.2026.128642_bb0045","series-title":"Learn the story of these life-saving jabs","author":"WHO","year":"2021"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijvsm.2018.05.001","article-title":"Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms","volume":"6","author":"El-Sayed","year":"2018","journal-title":"Int J Vet Sci Med"},{"key":"10.1016\/j.vaccine.2026.128642_bb0055","series-title":"aSH. Essential Tuberculosis. Cham, Switzerland: Springer Nature Switzerland AG","author":"Kaufmann","year":"2021"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0060","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","article-title":"100 years of mycobacterium bovis bacille Calmette-Guerin","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128642_bb0065","article-title":"Jonas Salk (1914-1995): pioneering the fight against polio and beyond","volume":"16","author":"Sahu","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.vaccine.2026.128642_bb0070","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128642_bb0075","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"MRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128642_bb0080","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102687","article-title":"The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases","volume":"36","author":"Chen","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0090","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","article-title":"The biogenesis, functions, and challenges of circular RNAs","volume":"71","author":"Li","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.vaccine.2026.128642_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.151095","article-title":"Nanovaccine based on chitosan oligosaccharide-polyethyleneimine packaged circRNA encoding sigma c proteins elicits protective immunity against novel duck reovirus in ducks","volume":"351","author":"Tian","year":"2026","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"40","key":"10.1016\/j.vaccine.2026.128642_bb0105","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1016\/j.vaccine.2020.10.059","article-title":"The public\u2019s role in COVID-19 vaccination: human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States","volume":"39","author":"Schoch-Spana","year":"2021","journal-title":"Vaccine"},{"issue":"10441","key":"10.1016\/j.vaccine.2026.128642_bb0110","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the expanded programme on immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"issue":"6465","key":"10.1016\/j.vaccine.2026.128642_bb0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aay6485","article-title":"Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens","volume":"366","author":"Mina","year":"2019","journal-title":"Science"},{"issue":"51","key":"10.1016\/j.vaccine.2026.128642_bb0120","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1073\/pnas.1717161115","article-title":"Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR","volume":"115","author":"Sevilla","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrmicro2536","article-title":"Shifting the balance: antibiotic effects on host-microbiota mutualism","volume":"9","author":"Willing","year":"2011","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128642_bb0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm1077","article-title":"A role for Streptococcus pneumoniae in virus-associated pneumonia","volume":"10","author":"Madhi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128642_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2020.108378","article-title":"Modeling the impact of mass influenza vaccination and public health interventions on COVID-19 epidemics with limited detection capability","volume":"325","author":"Li","year":"2020","journal-title":"Math Biosci"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128642_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens14020196","article-title":"Beyond tuberculosis: the surprising immunological benefits of the bacillus Calmette-Guerin (BCG) vaccine in infectious, auto-immune, and inflammatory diseases","volume":"14","author":"Jurczak","year":"2025","journal-title":"Pathogens"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128642_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157393","article-title":"Bacillus Calmette-Guerin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice","volume":"7","author":"Zhang","year":"2022","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128642_bb0150","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148291","article-title":"BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases","volume":"131","author":"Singh","year":"2021","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128642_bb0155","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2105\/AJPH.2020.306114","article-title":"The societal value of vaccination in the age of COVID-19","volume":"111","author":"Bloom","year":"2021","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2026.128642_bb0160","series-title":"Vaccination in acute humanitarian emergencies: A framework for decision making","author":"WHO","year":"2017"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128642_bb0165","first-page":"205","article-title":"Measles vaccines: WHO position paper - April 2017","volume":"92","author":"WHO","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128642_bb0170","series-title":"Measles Vaccine Recommendations","author":"Prevention USCfDCa","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128642_bb0175","series-title":"Measles and Rubella Prevention and Control Plan (2024 Edition)","author":"Administration NDCaP","year":"2024"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0180","first-page":"241","article-title":"National Immunization Program: Pediatric Vaccine Schedule and Technical Guidelines(2021 verson)","volume":"11","author":"NHCotPsRo C","year":"2021","journal-title":"Chin J Viral Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128642_bb0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.vaccine.2014.07.068","article-title":"Varicella and herpes zoster vaccines: WHO position paper, June 2014--recommendations","volume":"34","author":"WHO","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128642_bb0190","series-title":"Manual for the Surveillance of Vaccine-Preventable Diseases-Chapter 17:Varicella","author":"Prevention USCoDca","year":"2024"},{"issue":"01","key":"10.1016\/j.vaccine.2026.128642_bb0195","first-page":"4","article-title":"Diagnosis Treat Protocol Varicella (2023 edition)","volume":"31","author":"General Office of the National Health Commission of the People\u2019\u2019s Republic of China GDotNAoTCMotPsRoC","year":"2024","journal-title":"Chinese Medicine of the People\u2019s Republic of China"},{"key":"10.1016\/j.vaccine.2026.128642_bb0200","series-title":"Varicella Outbreak Identification, Investigation, & Control","author":"Prevention USCoDca","year":"2024"},{"issue":"47","key":"10.1016\/j.vaccine.2026.128642_bb0205","first-page":"521","article-title":"Meningococcal vaccines: WHO position paper, November 2011","volume":"86","author":"WHO","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128642_bb0210","series-title":"Manual for the Surveillance of Vaccine-Preventable Diseases--Chapter 14:Meningococcal Disease","author":"Prevention USCoDca","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128642_bb0215","series-title":"National meningococcal meningitis prevention and control work plan (Document No. 32, 2006)","author":"Ministry of Health PsRoC","year":"2006"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128642_bb0220","article-title":"Expert consensus on immunoprophylaxis of common respiratory pathogens in children","volume":"36","author":"Medicine NCfR","year":"2021","journal-title":"ChineseJ Appli Clin Pediatr"},{"key":"10.1016\/j.vaccine.2026.128642_bb0225","series-title":"Manual for the Surveillance of Vaccine-Preventable Diseases--Chapter :Hepatitis A","author":"Prevention USCoDca","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128642_bb0230","series-title":"Hepatitis A vaccines:WHO position paper","author":"WHO","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128642_bb0235","series-title":"Cholera vaccines: WHO position paper","author":"WHO","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128642_bb0240","series-title":"Cholera Outbreak Response--Section 9\uff1bOral Cholera Vaccine","author":"Control GTFoC","year":"2025"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCMA.0000000000000210","article-title":"Measles re-emerges and recommendation of vaccination","volume":"83","author":"Chen","year":"2020","journal-title":"J Chin Med Assoc"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128642_bb0250","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/21645515.2020.1780847","article-title":"Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States","volume":"17","author":"Talbird","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128642_bb0255","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1377\/hlthaff.2016.0462","article-title":"Modeling the economic burden of adult Vaccine-preventable diseases in the United States","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff"},{"key":"10.1016\/j.vaccine.2026.128642_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069317","article-title":"Public health impact of covid-19 vaccines in the US: observational study","volume":"377","author":"Suthar","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128642_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2021.112314","article-title":"Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: a global analysis","volume":"204","author":"Coccia","year":"2022","journal-title":"Environ Res"},{"issue":"49","key":"10.1016\/j.vaccine.2026.128642_bb0270","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1016\/j.vaccine.2019.09.086","article-title":"Exploring indirect protection associated with influenza immunization - a systematic review of the literature","volume":"37","author":"Friedman","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0275","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2020.06.011","article-title":"Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention","volume":"59","author":"Bartsch","year":"2020","journal-title":"Am J Prev Med"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128642_bb0280","article-title":"Use of information and communication technology strategies to increase vaccination coverage in older adults: a systematic review","volume":"11","author":"Buja","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2026.128642_bb0285","doi-asserted-by":"crossref","first-page":"C55","DOI":"10.1016\/j.vaccine.2015.04.028","article-title":"Typhoid fever vaccination strategies","volume":"33","author":"Date","year":"2015","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128642_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158485","article-title":"Effectiveness of SARS-CoV-2 vaccines for short- and Long-term immunity: a general overview for the pandemic contrast","volume":"23","author":"Inchingolo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0295","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12992-021-00745-w","article-title":"Advancing sustainable development goals through immunization: a literature review","volume":"17","author":"Decouttere","year":"2021","journal-title":"Glob Health"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0300","doi-asserted-by":"crossref","DOI":"10.2196\/14664","article-title":"A collaborative initiative to strengthen sustainable public health capacity for polio eradication and routine immunization activities in the eastern mediterranean region","volume":"5","author":"Al Gunaid","year":"2019","journal-title":"JMIR Public Health Surveill"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128642_bb0305","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/17441692.2017.1296172","article-title":"Future-proofing global health: governance of priorities","volume":"13","author":"Bennett","year":"2018","journal-title":"Glob Public Health"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128642_bb0310","doi-asserted-by":"crossref","first-page":"933","DOI":"10.26719\/2018.24.9.933","article-title":"Capacity building on health diplomacy: a training experience from Pakistan","volume":"24","author":"Shaikh","year":"2018","journal-title":"East Mediterr Health J"},{"issue":"S3","key":"10.1016\/j.vaccine.2026.128642_bb0315","doi-asserted-by":"crossref","DOI":"10.2105\/AJPH.2018.304527","article-title":"Taiwan\u2019s annual seasonal influenza mass vaccination program-lessons for pandemic planning","volume":"108","author":"Meyer","year":"2018","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pharma.2016.08.005","article-title":"Benefits of pharmacist-led flu vaccination services in community pharmacy","volume":"75","author":"Kirkdale","year":"2017","journal-title":"Ann Pharm Fr"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128642_bb0325","article-title":"The experience of an accelerated COVID-19 immunization campaign in Oman: a review within the WHO health system building blocks framework","volume":"13","author":"Al Ghafri","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0330","first-page":"363","article-title":"The role of pharmacies in the implementation of vaccination cover- age in Italy. Insights from the preliminary data of the lombardy region","volume":"36","author":"Pennisi","year":"2024","journal-title":"Ann Ig"},{"issue":"10317","key":"10.1016\/j.vaccine.2026.128642_bb0335","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/S0140-6736(21)02507-1","article-title":"Promoting COVID-19 vaccine acceptance: recommendations from the lancet commission on vaccine refusal, acceptance, and demand in the USA","volume":"398","author":"Omer","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128642_bb0340","article-title":"The governance of childhood vaccination services in crisis settings: a scoping review","volume":"11","author":"Abdelmagid","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128642_bb0345","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"85","author":"von Elm","year":"2007","journal-title":"Bull World Health Organ"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128642_bb0350","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.8.2400450","article-title":"COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six european countries, 2021 to 2022","volume":"30","author":"Soares","year":"2025","journal-title":"Euro Surveill"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0355","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0360","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70081","article-title":"Effectiveness of the XBB.1.5 COVID-19 vaccines against SARS-CoV-2 hospitalisation among adults aged >\/= 65 years during the BA.2.86\/JN.1 predominant period, VEBIS hospital study, Europe, November 2023 to May 2024","volume":"19","author":"Antunes","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0365","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2474772","article-title":"Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: a systematic literature review","volume":"21","author":"Rudolph","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128642_bb0370","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cmi.2021.06.036","article-title":"BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel","volume":"27","author":"Brosh-Nissimov","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"441","key":"10.1016\/j.vaccine.2026.128642_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2345","article-title":"The broad socioeconomic benefits of vaccination","volume":"10","author":"Bloom","year":"2018","journal-title":"Sci Transl Med"},{"issue":"220 Suppl 4","key":"10.1016\/j.vaccine.2026.128642_bb0380","article-title":"Neisseria meningitidis serogroup w meningitis epidemic in Togo, 2016","volume":"220","author":"Mounkoro","year":"2019","journal-title":"J Infect Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2026.128642_bb0385","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.15585\/mmwr.mm6649a3","article-title":"Large outbreak of neisseria meningitidis serogroup c - Nigeria, december 2016-June 2017","volume":"66","author":"Nnadi","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0390","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14760584.2024.2387599","article-title":"The broader benefits of vaccines: methodologies for inclusion in economic evaluation","volume":"23","author":"Simoens","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"30","key":"10.1016\/j.vaccine.2026.128642_bb0395","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.vaccine.2022.04.050","article-title":"Capturing the value of vaccination within health technology assessment and health economics: literature review and novel conceptual framework","volume":"40","author":"Beck","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128642_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02130","article-title":"Viral emerging diseases: challenges in developing vaccination strategies","volume":"11","author":"Trovato","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128642_bb0405","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/cei.13284","article-title":"Vaccines for emerging pathogens: prospects for licensure","volume":"198","author":"Williamson","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2026.128642_bb0410","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0415","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14760584.2022.2027240","article-title":"The next major emergent infectious disease: reflections on vaccine emergency development strategies","volume":"21","author":"Bai","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0420","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01627-23","article-title":"Translational success of fundamental virology: a VSV-vectored ebola vaccine","volume":"98","author":"Anderson","year":"2024","journal-title":"J Virol"},{"issue":"10068","key":"10.1016\/j.vaccine.2026.128642_bb0425","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing ebola virus disease: final results from the guinea ring vaccination, open-label, cluster-randomised trial (ebola ca suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128642_bb0430","series-title":"WHO: Ebola situation report","author":"WHO","year":"2015"},{"key":"10.1016\/j.vaccine.2026.128642_bb0435","series-title":"Technical guideline on use of inactivated enterovirus 71 vaccine(2016)","author":"Prevention CCfDCa","year":"2016"},{"key":"10.1016\/j.vaccine.2026.128642_bb0440","article-title":"Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: a population-based study","volume":"20","author":"Hong","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2026.128642_bb0445","article-title":"Surveillance, epidemiology and impact of EV-A71 vaccination on hand, foot, and mouth disease in Nanchang, China, 2010-2019","volume":"12","author":"He","year":"2021","journal-title":"Front Microbiol"},{"issue":"25","key":"10.1016\/j.vaccine.2026.128642_bb0450","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.vaccine.2021.05.009","article-title":"The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine","volume":"39","author":"Wang","year":"2021","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128642_bb0455","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3201\/eid2410.171953","article-title":"Emerging enteroviruses causing hand, foot and mouth disease, China, 2010-2016","volume":"24","author":"Li","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0460","article-title":"Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012-2016","volume":"7","author":"Wang","year":"2018","journal-title":"Emer Microbes Infect"},{"key":"10.1016\/j.vaccine.2026.128642_bb0465","series-title":"Key Facts About Seasonal Flu Vaccine","author":"Prevention USCfDCa","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128642_bb0470","series-title":"Past Seasons' Vaccine Effectiveness Estimates","author":"Prevention USCfDCa","year":"2026"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0475","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128642_bb0480","series-title":"WHO Research and Development blueprint evaluation of ideas for potential platforms to support development and production of health technologies for priority infectious diseases with epidemic potential","author":"WHO","year":"2016"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128642_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30123-7","article-title":"Disease x: accelerating the development of medical countermeasures for the next pandemic","volume":"20","author":"Simpson","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0490","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"MRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2026.128642_bb0495","series-title":"A proposed model to build capacity for emergency use authorization for vaccines: Guidance for national regulatory authorities","author":"Jl","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128642_bb0500","series-title":"Vaccine administration law of the People\u2019s Republic of China","author":"China NPsCotPsRo","year":"2019"},{"key":"10.1016\/j.vaccine.2026.128642_bb0505","series-title":"Notice on issuing five technical guidelines including \"Technical guidelines for development of COVID-19 preventive vaccines (Trial)\"","author":"Center for Drug Evaluation N","year":"2020"},{"key":"10.1016\/j.vaccine.2026.128642_bb0510","series-title":"Racing against the epidemic: On-site drug registration inspections accelerate COVID-19 therapeutic development","author":"Administration NMP","year":"2020"},{"key":"10.1016\/j.vaccine.2026.128642_bb0515","first-page":"12","article-title":"International comparison and insights on vaccine policies and regulatory system","volume":"11","author":"Qian","year":"2022","journal-title":"China Food Drug Admin Magazine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128642_bb0520","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128642_bb0525","article-title":"An analysis on the policies of conditional marketing authorisation for medicine and its implementation effects in EU","volume":"50","author":"Xuan","year":"2019","journal-title":"Inese J Pharma"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128642_bb0530","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jis923","article-title":"Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events","volume":"207","author":"De Serres","year":"2013","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128642_bb0535","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S1473-3099(19)30231-2","article-title":"Measles resurgence in the USA: how international travel compounds vaccine resistance","volume":"19","author":"Sarkar","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128642_bb0540","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/bca.2020.12","article-title":"The benefits and costs of using social distancing to flatten the curve for COVID-19","volume":"11","author":"Thunstr\u00f6m","year":"2020","journal-title":"J Benefit-Cost Analysis"},{"key":"10.1016\/j.vaccine.2026.128642_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2020.103854","article-title":"Editor\u2019s choice: influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: a survey","volume":"114","author":"Kwok","year":"2021","journal-title":"Int J Nurs Stud"},{"key":"10.1016\/j.vaccine.2026.128642_bb0550","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijid.2021.02.007","article-title":"Increasing vaccine acceptance using evidence-based approaches and policies: insights from research on behavioural and social determinants presented at the 7th annual vaccine acceptance meeting","volume":"105","author":"Attwell","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0555","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.0804","article-title":"Fear of adverse effects and COVID-19 vaccine hesitancy: recommendations of the treatment expectation expert group","volume":"2","author":"Rief","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128642_bb0560","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries","volume":"27","author":"Solis Arce","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0565","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10393-021-01524-0","article-title":"Hesitancy toward a COVID-19 vaccine","volume":"18","author":"Thunstrom","year":"2021","journal-title":"Ecohealth"},{"issue":"41","key":"10.1016\/j.vaccine.2026.128642_bb0570","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1016\/j.vaccine.2020.08.017","article-title":"So much at stake: ethical tradeoffs in accelerating SARSCoV-2 vaccine development","volume":"38","author":"Grady","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128642_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.700213","article-title":"Risk, trust, and flawed assumptions: Vaccine hesitancy during the COVID-19 pandemic","volume":"9","author":"Ebrahimi","year":"2021","journal-title":"Front Public Health"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128642_bb0580","doi-asserted-by":"crossref","first-page":"434","DOI":"10.34172\/hpp.2021.54","article-title":"Addressing COVID-19 vaccine hesitancy: lessons from the role of community participation in previous vaccination programs","volume":"11","author":"Afolabi","year":"2021","journal-title":"Health Promot Perspect"},{"issue":"sup1","key":"10.1016\/j.vaccine.2026.128642_bb0585","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/10810730.2016.1253122","article-title":"Community engagement in Liberia: routine immunization Post-Ebola","volume":"22","author":"Bedford","year":"2017","journal-title":"J Health Commun"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128642_bb0590","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix068","article-title":"Legacy of polio-use of India\u2019s social mobilization network for strengthening of the universal immunization program in India","volume":"216","author":"Deutsch","year":"2017","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0595","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s12889-018-5724-y","article-title":"A postpartum vaccination promotion intervention using motivational interviewing techniques improves short-term vaccine coverage: PromoVac study","volume":"18","author":"Gagneur","year":"2018","journal-title":"BMC Public Health"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128642_bb0600","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.36.1800641","volume":"24","author":"Gagneur","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128642_bb0605","series-title":"Free curriculum-linked lessons developed by teachers, for teachers!","author":"Immunity","year":"2026"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128642_bb0610","doi-asserted-by":"crossref","DOI":"10.2196\/12851","article-title":"Personalized text messages and automated calls for improving vaccine coverage among children in Pakistan: protocol for a community-based cluster randomized clinical trial","volume":"8","author":"Kazi","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.vaccine.2026.128642_bb0615","series-title":"Coronavirus disease 2019 (COVID-19)Situation Report \u2013 86","author":"WHO","year":"2020"},{"issue":"7809","key":"10.1016\/j.vaccine.2026.128642_bb0620","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/d41586-020-01452-z","article-title":"The epic battle against coronavirus misinformation and conspiracy theories","volume":"581","author":"Ball","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128642_bb0625","doi-asserted-by":"crossref","DOI":"10.2196\/55642","article-title":"When infodemic meets epidemic: systematic literature review","volume":"11","author":"Asaad","year":"2025","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.vaccine.2026.128642_bb0630","series-title":"Public Sentiment on Governmental COVID-19 Measures in Dutch Social Media. Proceedings of the 1st Workshop on NLP for COVID-19 (Part 2)","author":"Wang","year":"2020"},{"key":"10.1016\/j.vaccine.2026.128642_bb0635","series-title":"Emotion Bubbles: Emotional Composition of Online Discourse Before and After the COVID-19 Outbreak. Proceedings of the Acm Web Conference","author":"Zhunis","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128642_bb0640","series-title":"Sentiment Analysis and Topic Modelling of Indian Government\u2019s Twitter Handle #IndiaFightsCorona. Proceedings of the International Conference on Transfer and Diffusion of IT; Tiruchirappalli, India","author":"Shah","year":"2020"},{"key":"10.1016\/j.vaccine.2026.128642_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.is.2022.102054","article-title":"Mining association rules from COVID-19 related twitter data to discover word patterns, topics and inferences","volume":"109","author":"Koukaras","year":"2022","journal-title":"Inf Syst"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128642_bb0650","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"MRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128642_bb0655","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol J"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128642_bb0660","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2021.03.004","article-title":"Developing standard safety outcomes for COVID-19 vaccines","volume":"39","author":"Buttery","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128642_bb0665","author":"WHO"},{"issue":"32","key":"10.1016\/j.vaccine.2026.128642_bb0670","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.vaccine.2017.06.033","article-title":"Guide to active vaccine safety surveillance: report of CIOMS working group on vaccine safety - executive summary","volume":"35","author":"Heininger","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128642_bb0675","author":"WHO"},{"key":"10.1016\/j.vaccine.2026.128642_bb0680","author":"WHO"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128642_bb0685","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2100173","article-title":"Information systems for vaccine safety surveillance","volume":"18","author":"Buttery","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"31","key":"10.1016\/j.vaccine.2026.128642_bb0690","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2020.04.056","article-title":"Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in australian pregnant women using AusVaxSafety","volume":"38","author":"Glover","year":"2020","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128642_bb0695","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1016\/j.vaccine.2021.10.019","article-title":"Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: findings from the CDC v-safe surveillance system","volume":"39","author":"Chapin-Bardales","year":"2021","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2026.128642_bb0700","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1093\/cid\/civ551","article-title":"Introduction and rollout of a new group a meningococcal conjugate vaccine (PsA-TT) in African meningitis belt countries, 2010-2014","volume":"61","author":"Djingarey","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128642_bb0705","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal a conjugate vaccine in africans","volume":"364","author":"Sow","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:15:17Z","timestamp":1783113317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":141,"alternative-id":["S0264410X26004500"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128642","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination strategies for responding to public health emergencies of infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128642"}}